Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Meningeal inflammation produced by cryptococcus neoformans, an encapsulated yeast that tends to infect individuals with acquired immunodeficiency syndrome and other immunocompromised states. The organism enters the body through the respiratory tract, but symptomatic infections are usually limited to the lungs and nervous system. The organism may also produce parenchymal brain lesions (torulomas). Clinically, the course is subacute and may feature headache; nausea; photophobia; focal neurologic deficits; seizures; cranial neuropathies; and hydrocephalus. (From Adams et al., Principles of Neurology, 6th ed, pp721-2)
Biomarker and diagnostic research for Cryptococcal meningitis has been reported in the published literature.
1 FDA-approved treatment is available for Cryptococcal meningitis, including AMPHOTERICIN B (AMBISOME, approved 1997). An additional 2 compounds hold orphan drug designation.
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
6 clinical trials registered, 4 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE4, 1 PHASE3, 2 PHASE2. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06666322](https://clinicaltrials.gov/study/NCT06666322) |
Data assembled from 4 of 12 sources · Last updated Sep 17, 2026, 10:31 PM UTC
Common questions about Cryptococcal meningitis
AMBISOME |
AMPHOTERICIN B |
— |
1997 |
Available |
The following drugs have received orphan drug designation from the FDA for Cryptococcal meningitis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
Flucytosine Injection for intravenous Infusion | Flucytosine Injection for intravenous Infusion | Cipla Ltd. | 2023 | — | Designated |
selective inhibitor of fungal lanosterol demethylase | selective inhibitor of fungal lanosterol demethylase | Viamet Pharmaceuticals, Inc. | 2014 | — | Withdrawn |
Gene therapy approaches for Cryptococcal meningitis have been reported in the published literature.
6 trials found
Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)
PHASE2 |
David Boulware |
RECRUITING |
[NCT03945448](https://clinicaltrials.gov/study/NCT03945448) | Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia | PHASE2 | Makerere University | RECRUITING |
[NCT00001352](https://clinicaltrials.gov/study/NCT00001352) | Fungal Infection Susceptibility | — | National Institute of Allergy and Infectious Diseases (NIAID) | RECRUITING |
[NCT00867269](https://clinicaltrials.gov/study/NCT00867269) | Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia | — | National Institute of Allergy and Infectious Diseases (NIAID) | RECRUITING |
[NCT06178627](https://clinicaltrials.gov/study/NCT06178627) | Amphotericin B for Non-HIV Cryptococcal Meningitis Patients | PHASE4 | Huashan Hospital | UNKNOWN |
243 publications have been identified in PubMed for Cryptococcal meningitis. Kisho has analyzed 174 by research type. Research spans Basic Science / Preclinical (21%), Epidemiology / Natural History (19%), and Case Report / Case Series (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 36 | 21% |
Disease patterns and progression | 33 | 19% |
Patient case studies | 30 | 17% |
Research summaries | 27 | 16% |
Testing and diagnosis research | 24 | 14% |
Clinical study results | 17 | 10% |
New treatment approaches | 6 | 3% |
Other research | 1 | 1% |
Huang Y (2026). [PMID: 41485489](https://pubmed.ncbi.nlm.nih.gov/41485489/). *J Control Release*. [Basic Science / Preclinical]
Liu J (2026). [PMID: 42241274](https://pubmed.ncbi.nlm.nih.gov/42241274/). *Drug Deliv*. [Gene Therapy / Novel Therapeutics]
Yoon H (2026). [PMID: 41569033](https://pubmed.ncbi.nlm.nih.gov/41569033/). *Med Mycol*. [Epidemiology / Natural History]
Liang Y (2026). [PMID: 41105332](https://pubmed.ncbi.nlm.nih.gov/41105332/). *Eur J Clin Microbiol Infect Dis*. [Diagnostic / Biomarker]
Ellis J (2026). [PMID: 41662846](https://pubmed.ncbi.nlm.nih.gov/41662846/). *Lancet HIV*. [Clinical Trial Publication]
Link A (2026). [PMID: 41525300](https://pubmed.ncbi.nlm.nih.gov/41525300/). *PLOS global public health*. [Epidemiology / Natural History]
Numahata K (2026). [PMID: 42156049](https://pubmed.ncbi.nlm.nih.gov/42156049/). *Brain Nerve*. [Review / Meta-Analysis]
Chen L (2026). [PMID: 41547781](https://pubmed.ncbi.nlm.nih.gov/41547781/). *BMC infectious diseases*. [Clinical Trial Publication]
Hellmann MJ (2026). [PMID: 42221363](https://pubmed.ncbi.nlm.nih.gov/42221363/). *Cell Surf*. [Clinical Trial Publication]
Liu J (2026). [PMID: 41535605](https://pubmed.ncbi.nlm.nih.gov/41535605/). *Mycopathologia*. [Clinical Trial Publication]
AI-curated news mentioning Cryptococcal meningitis
Updated May 9, 2026
A case report highlights cryptococcal meningitis in a patient with VEXAS syndrome, contributing to the understanding of complications associated with this rare disease. This study underscores the need for awareness and management strategies for infections in patients with VEXAS syndrome.
Cases of recreational water illnesses, particularly cryptosporidiosis, are on the rise, posing a significant public health challenge. The chlorine-resistant parasite is expected to become an even bigger concern in the future.